Hence, agents or compounds, especially from natural origin, that possess antioxidant/anti-inflammatory may be considered as a candidate to mitigate MTX-induced AKI through both Nrf-2/Keap-1 and p38MAPK/NF-κB pathways, which have become attractive signaling targets for drug activities. This evidence concerns the gene NFKB1 and acute kidney injury.